Panchkula (DSLA); The CCI judgments arise from one original information filed by Shri Vivek Sharma under Section 19(1)(a) of the Competition Act, 2002. Initially, the Informant alleged contravention of Sections 3 and 4 of the Act against Becton Dickinson India Pvt. Ltd. and Max Super Specialty Hospital, Patparganj. The original allegation focused on higher MRP on disposable syringes sold through the hospital’s in-house pharmacy when compared with the same product available in the open market.

However, the case later moved beyond one syringe-pricing allegation. After investigation and supplementary investigation, the matter became a wider inquiry into private hospital billing practices in Delhi. Specifically, the DG examined whether private super-specialty hospitals abused their position over admitted in-patients by charging high prices for room rent, medical tests, medical devices, medicines, and consumables.

Therefore, the central public-interest question became larger:

Can private hospitals exploit admitted in-patients through captive billing for medicines, consumables, tests, devices, and hospital-linked services?

This question matters because admitted patients do not behave like ordinary consumers in an open market. Once treatment begins, they often face urgency, anxiety, information gaps, and practical dependence on the hospital. As a result, healthcare billing becomes not only a pricing issue, but also a competition, transparency, and consumer-choice issue.

2. Same Informant, Same Core Issues, but Separate Hospital-Wise Cases

The uploaded judgments involve the same original Informant and the same broad competition-law concern. Nevertheless, CCI later treated the matter as 12 separate hospital-wise sub-cases.

CCI recorded that the DG investigated 12 super-specialty hospitals. It also held that data relating to one hospital had no direct relation with the inquiry against another hospital. Consequently, CCI directed separate reports, separate public versions, and separate hearings.

2.1 Position in Simple Terms

Thus, CCI protected procedural fairness by examining each hospital separately. However, this method also diluted the systemic nature of the healthcare-pricing issue. In other words, the same public-interest concern survived across all sub-cases, but the legal analysis became fragmented.

3. Hospitals Covered in the Uploaded Orders

The uploaded orders cover 12 hospital-wise sub-cases.

This wide coverage shows why the matter had sector-level importance. Moreover, it shows that the case was not only about one hospital’s billing practice, but about a larger pattern alleged across leading private healthcare institutions.

4. Procedural Background

CCI ordered investigation under Section 26(1) on 17.11.2015 after forming a prima facie view under Section 4. Thereafter, the DG submitted an investigation report. Later, CCI noticed that the DG had referred to conduct resembling aftermarket abuse, but had not examined that issue in sufficient detail. Therefore, CCI directed supplementary investigation.

During supplementary investigation, the DG examined five major heads:

1. room rent;
2. medical tests;
3. medical devices;
4. consumables; and
5. medicines.

The DG then found that 12 hospitals were enterprises, that each hospital formed a separate relevant market for admitted in-patients, and that each hospital abused its dominant position in that market.

However, CCI did not finally accept the DG’s abuse findings. Instead, it scrutinised the DG’s methodology and ultimately closed the matters. Therefore, the case demonstrates a major gap between investigative findings and final adjudication.

5. Core Legal Issue

The core legal issue was:

Whether each private super-specialty hospital became dominant over its admitted in-patients and abused that dominance by charging unfair or excessive prices for hospital-linked products and services.

This issue required CCI to examine several connected questions.

Thus, the dispute required legal, economic, healthcare, and consumer-protection analysis. Moreover, because the case involved admitted patients, CCI also needed to examine real-world choice, not merely theoretical market options.

6. CCI’s Main Reasoning

CCI accepted that private hospitals provide healthcare services for monetary consideration. Therefore, hospitals qualify as enterprises under Section 2(h) of the Competition Act. The DG also recorded this finding during supplementary investigation.

However, CCI did not accept the DG’s core abuse methodology. The Commission found that the DG’s pricing comparisons were not strong enough to prove excessive or unfair pricing under Section 4.

6.1 Why CCI Rejected the DG’s Method

The DG compared hospital room rent with hotel room rent. It also compared diagnostic test prices with standalone diagnostic labs. Further, it compared procurement prices with selling prices.

However, hospitals argued that these comparisons ignored clinical infrastructure, 24×7 service, trained staff, emergency systems, quality assurance, inventory costs, and operational overheads. CCI found these concerns relevant.

Consequently, CCI moved away from the DG’s abuse findings and closed the matters. Therefore, CCI treated high margins as insufficient unless the DG could prove excessive and unfair pricing through proper legal-economic analysis.

7. Critical Analysis

7.1 CCI Correctly Avoided a Blanket Finding Against All Hospitals

CCI was right to avoid one blanket liability finding against all hospitals. Each hospital had different infrastructure, price systems, admission policies, pharmacy arrangements, cost structures, and billing practices.

Therefore, CCI could not fairly impose one common penalty merely because the public-interest issue was common. Moreover, hospital-wise assessment protected natural justice.

However, this fairness-based approach should not have ended the larger inquiry. CCI could still have separated liability while issuing common prospective directions on transparency and patient choice.

7.2 Separate Sub-Cases Weakened the Systemic Healthcare Lens

Nevertheless, the separate sub-case approach weakened the wider systemic analysis.

The real issue was not merely whether one hospital overcharged for one item. Rather, the deeper issue was whether private hospital billing systems make admitted patients commercially captive.

After admission, a patient and family may not freely compare prices, buy medicines from outside, shift hospitals, question every consumable, delay treatment for price verification, or negotiate with the hospital pharmacy.

Therefore, CCI should have balanced hospital-wise fairness with sector-wide patient vulnerability. Furthermore, it should have examined whether similar practices across hospitals created a broader market pattern that affected consumer choice.

7.3 DG Identified the Right Problem but Built a Weak Case

The DG correctly recognised a serious concern: admitted patients may become captive consumers.

However, the DG’s legal-economic method was weak. Excessive pricing cannot rest only on the difference between procurement price and selling price. Hospitals incur storage costs, staff costs, 24×7 availability costs, emergency service costs, quality-control costs, and inventory risk.

Similarly, hospital rooms cannot be compared mechanically with hotel rooms. A hospital room includes clinical infrastructure, nursing support, emergency response, infection-control systems, and medical risk.

Thus, DSLA’s balanced view is:

The DG identified the right public-interest problem, but failed to build a legally sustainable economic foundation.

7.4 CCI Was Right That High Margin Alone Is Not Abuse

CCI’s legal caution is understandable. Competition law does not punish every high price. Section 4 requires abuse of dominance through unfair or discriminatory price or condition.

Therefore, the DG needed to prove both:

1. that the price was excessive in relation to cost or economic value; and
2. that the price was unfair in itself or unfair compared with proper market comparables.

If the DG failed to establish these elements, CCI could not impose penalty merely on moral concern. Nevertheless, CCI could have used the case to improve future market conduct through behavioural directions.

7.5 MRP Compliance Cannot Be the Final Answer

At the same time, MRP compliance cannot automatically prove fairness in a captive in-patient setting.

MRP is only the maximum retail price. A hospital may procure a product at a deep institutional discount and sell it at full MRP to a patient who cannot realistically buy from outside during treatment.

Therefore, MRP compliance may protect hospitals from one kind of illegality. However, it should not end the competition-law and patient-protection inquiry. Instead, it should lead to a deeper question: whether the patient had real choice and clear disclosure before paying.

8. The 11-Year Delay and the Competition Act Mandate

This case took nearly 11 years from the 2015 information to the final closure orders. Therefore, the delay raises a serious statutory-mandate concern.

CCI’s governing mandate under the Competition Act is not merely to dispose of cases. It must protect competition, consumer interest, and freedom of trade in Indian markets.

In a healthcare-pricing case, this mandate becomes especially important because patients suffer harm in real time. If CCI closes a case after 11 years because the DG methodology was weak, then the patient-protection purpose of competition law becomes practically ineffective.

8.1 DSLA View on Delay

DSLA’s position is clear:

An 11-year public-interest healthcare-pricing case should not end only with closure. Even if penalty was not justified, CCI should have considered prospective transparency directions.

Such directions would not punish hospitals. Instead, they would improve market conduct for the future. Moreover, they would show that competition law can respond to public-interest market failures even when penalty cannot legally stand.

9. DG Report Failure and CCI’s Institutional Responsibility

The uploaded orders show a serious institutional concern.

The DG found abuse against 12 hospitals. However, CCI did not finally accept the DG’s abuse finding in the uploaded set.

9.1 DG Report Success Rate in Uploaded Vivek Sharma Orders

Important caution: This percentage applies only to the uploaded Vivek Sharma hospital-pricing orders. It is not CCI’s overall DG success rate in all cases.

9.2 Why the 0% Outcome Matters

This outcome raises a serious question:

If the DG’s methodology was so weak, why did the defects survive original investigation, supplementary investigation, revised reports, and nearly 11 years of proceedings?

CCI did not merely receive one accidental defective report. It had already directed supplementary investigation after noticing gaps in aftermarket abuse analysis. Therefore, when the supplementary reports still failed, institutional responsibility cannot fall only on the DG.

Moreover, an informant cannot control the DG’s methodology. Consequently, when the investigative arm fails, the public-interest case suffers even if the underlying concern remains real.

10. Question on DG Selection, Assignment, and Supervision

These cases also raise questions about selection, assignment, supervision, and expert support for DG investigations.

Excessive-pricing and hospital-aftermarket cases require specialised expertise.

If the DG team did not have adequate economic and healthcare expertise, the report could identify the right issue but fail the legal test.

Therefore, DSLA says:

The failure of all 12 DG abuse findings before CCI raises a question not only about the DG report, but also about CCI’s supervision of investigation quality in a decade-old public-interest case.

In addition, CCI should have explained whether it used sufficient economic expertise before rejecting the DG’s methodology and closing the matters.

11. If the DG Report Was Weak, Why Did CCI Accept It?

This point requires an important distinction.

CCI “accepted” the DG report only procedurally. It placed the report on record, circulated it, invited objections, and heard parties. However, that procedural acceptance did not mean CCI accepted the DG’s findings on merits.

Nevertheless, this still raises a deeper concern. If CCI found the DG report weak after final hearing, it should have considered a stronger corrective path.

11.1 Possible Corrective Steps

CCI could have considered:

1. further focused investigation;
2. expert economic assistance;
3. clarification from DG officers;
4. better comparables;
5. hospital-wise pricing benchmarks; or
6. prospective behavioural directions.

Instead, CCI closed the matters.

Thus, DSLA’s view is:

CCI did not accept the DG’s findings on merits, but it should have explained why such weak methodology remained unresolved despite long supervision and supplementary investigation.

12. Did the DG Defend Its Report?

The uploaded orders do not clearly show that the DG separately appeared and defended its report like a party during final hearings.

For example, the “PRESENT” portion in Case No. 77(1) mentions the Informant and the hospital’s counsel/representatives. It does not show DG counsel or DG officers appearing as a separate defending side.

This matters because the Informant alone should not bear the burden of defending every technical aspect of the DG’s economic methodology.

12.1 DSLA Concern

DSLA’s concern is direct:

If DG finds abuse in 12 hospital-wise reports, but CCI later rejects the methodology in all 12, the record should show whether DG clarified or defended the investigation method before CCI.

This does not mean DG must act like a private litigant. However, it means CCI should ensure that the investigative reasoning receives technical clarification before final closure. Otherwise, the case becomes unfairly dependent on the Informant’s ability to defend an investigation he did not conduct.

13. Are There Provisions for DG Defence?

There is no clear statutory framework that makes the DG an adversarial party who must defend the report like the Informant or Opposite Party.

The DG’s role is investigative. CCI’s role is adjudicatory.

However, CCI has procedural control. It can require further investigation, seek clarification, call for additional material, or direct better investigation. Therefore, even if DG has no formal “defence” role, CCI can still ensure that the DG’s methodology receives technical clarification before final closure.

13.1 DSLA Position

DSLA’s position is:

The DG may not have a formal right to argue like a party, but CCI has enough authority to require clarification, further investigation, or expert-supported analysis in complex public-interest matters.

Accordingly, CCI should have used that authority more actively before closing a long-running healthcare-pricing case.

14. Informant’s Burden and Cost Concern

The Vivek Sharma cases also raise a serious fairness issue for informants.

An informant may spend years, money, documents, expert effort, and legal resources to bring a public-interest competition case. However, if the DG investigation fails due to weak methodology, the informant may lose the case without receiving meaningful relief.

Normally, the informant bears his own cost. However, where a decade-old matter fails because of investigative defects, the informant may seek costs in appeal or ask the appellate forum to record prejudice.

14.1 DSLA View on Informant’s Burden

DSLA says:

A public-interest informant should not be left helpless when the regulator’s own investigative arm fails to build a legally sustainable record.

Therefore, where the DG report fails because of methodology, the informant should not carry the entire burden of institutional failure. Instead, CCI should recognise the public-interest effort and consider corrective procedural options.

15. Should CCI Have Issued Public-Interest Directions?

Yes. DSLA believes CCI should have considered limited public-interest directions.

CCI may have been legally justified in refusing penalty due to weak DG methodology. However, CCI did not have to treat the case only as “penalty or closure.”

A better approach would have been:

No penalty due to weak proof, but prospective directions for billing transparency, patient choice, outside-purchase disclosure, and record-keeping.

Such directions would remain within CCI’s mandate because they would protect consumer interest, reduce information asymmetry, improve freedom of trade, and prevent patient lock-in. Moreover, these directions would not require CCI to fix prices.

16. Possible Directions CCI Could Have Issued

CCI could have issued limited behavioural directions without fixing hospital prices.

These directions would not make CCI a hospital price regulator. Rather, they would improve market transparency and patient choice. In addition, they would create a record for future enforcement if hospitals continued restrictive billing practices.

17. Strengths of the CCI Judgments

The judgments have several strengths.

Therefore, the orders are not legally reckless. They show caution and evidentiary discipline. However, legal caution should have been paired with prospective safeguards.

18. Weaknesses of the CCI Judgments

However, the judgments also suffer from important weaknesses.

Thus, the orders are legally cautious but institutionally incomplete. Moreover, they show that procedural fairness for hospitals and practical protection for patients were not fully balanced.

19. What DSLA Says

DSLA says the Vivek Sharma judgments expose a serious gap between competition-law proof, regulatory investigation quality, and patient hardship.

CCI was right to refuse penalty if the DG failed to prove excessive or unfair pricing through proper evidence. However, CCI should not have closed an 11-year healthcare-pricing matter without any prospective safeguards.

The case involved admitted patients, hospital pharmacies, consumables, medicines, medical devices, diagnostic tests, and billing opacity. Therefore, it was not an ordinary commercial pricing dispute. It affected life, health, family finances, and consumer dignity.

19.1 DSLA’s Key View

DSLA says:

CCI’s closure may be legally defensible on evidentiary grounds. However, the absence of public-interest directions makes the judgments incomplete from the standpoint of patient protection and market accountability.

Furthermore, DSLA believes that CCI should have separated penalty from reform. Even if penalty failed, reform-oriented directions could still have improved market transparency.

20. DSLA’s Final Conclusion

The uploaded CCI judgments are legally cautious but institutionally troubling.

They show that CCI protected hospitals from penalty based on weak DG methodology. That part is legally understandable. However, the broader record raises five serious questions:

1. Why did an 11-year investigation fail on methodology?
2. Why did all 12 DG abuse findings fail before CCI?
3. Why did CCI not cure defects through further focused investigation or expert support?
4. Why did the final orders not issue even limited patient-facing transparency directions?
5. Why should the Informant bear the burden of a public-interest case when the regulator’s investigation failed?

Therefore, DSLA’s final view is:

The Vivek Sharma hospital-pricing judgments should not be read as a clean endorsement of private hospital billing practices. Instead, they should be read as a warning that India needs stronger competition-sensitive healthcare billing rules, better DG investigation quality, and clearer public-interest directions where patient choice and market transparency are at stake.

Ultimately, the cases show that competition law must do more than close files after long investigations. It must also preserve market confidence, protect vulnerable consumers, and ensure that public-interest informants do not carry the cost of institutional weakness alone.

Also, Read DSLA Analysis of CCI Order:

Critical Analysis of CCI Interim Order in Venky’s Poultry Case